Neurimmune Holding AG:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Neurimmune Holding AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7580
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Neurimmune Holding AG (Neurimmune), formerly Neurimmune Therapeutics AG is a biopharmaceutical company that develops immunotherapeutics for human diseases. The company’s pipeline products include human-derived monoclonal antibodies developed for the treatment and prevention of human neurodegenerative disorders through preclinical development. It develops reverse translational medicine technology platform which creates recombinant human-derived monoclonal antibodies as therapeutics. Neurimmune’s human-derived monoclonal antibodies are used as drug candidates in the treatment of diseases such as Alzheimer’s disease, Parkinson’s disease, central nervous system disorders, transthyretin amyloidosis, type-2 diabetes, tauopathies and amyotrophic lateral sclerosis. The company also conducts research and development programs on progressive multifocal leukoencephalopathy, neuropathy, Huntington’s disease and cardiomyopathy. Neurimmune is headquartered in Zurich, Switzerland.

Neurimmune Holding AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neurimmune Holding AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
AL-S Pharma Secures Investment from Neurimmune and TVM Capital Life Science Venture Capital 10
Partnerships 11
Biogen Exercises Option Agreement with Neurimmune 11
Neurimmune Therapeutics Enters into Co-Development Agreement with Ono Pharma 12
Ramot at Tel Aviv University Enters into Research Agreement with Neurimmune 13
ALS TDI and Anelixis Therapeutics Enters into Research Agreement with Neurimmune 14
Licensing Agreements 15
Mabimmune Enters into Collaborative Research Agreement with Neurimmune 15
Neurimmune Holding AG – Key Competitors 16
Neurimmune Holding AG – Key Employees 17
Neurimmune Holding AG – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Corporate Communications 19
Sep 12, 2018: Neurimmune names Christoph Hock as Chief Medical Officer to lead clinical development 19
Apr 26, 2018: Neurimmune appoints Fabian Buller as Chief Business Officer 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Key Facts 2
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neurimmune Holding AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neurimmune Holding AG, Deals By Therapy Area, 2012 to YTD 2018 8
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
AL-S Pharma Secures Investment from Neurimmune and TVM Capital Life Science Venture Capital 10
Biogen Exercises Option Agreement with Neurimmune 11
Neurimmune Therapeutics Enters into Co-Development Agreement with Ono Pharma 12
Ramot at Tel Aviv University Enters into Research Agreement with Neurimmune 13
ALS TDI and Anelixis Therapeutics Enters into Research Agreement with Neurimmune 14
Mabimmune Enters into Collaborative Research Agreement with Neurimmune 15
Neurimmune Holding AG, Key Competitors 16
Neurimmune Holding AG, Key Employees 17

List of Figures
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Neurimmune Holding AG:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Miltenyi Biotec GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Miltenyi Biotec GmbH (Miltenyi) is a biotechnology company which provides biomedical research and cellular therapy products for cell isolation, flow cytometry, sample preparation and cell culture. The company's services include sample preparation, cell separation, flow cytometry, cell cultur …
  • Robert Walters Plc (RWA):企業の財務・戦略的SWOT分析
    Summary Robert Walters Plc (Robert Walters) is a recruitment and consultancy service provider. The company offers placements of professionals on permanent, contract and interim positions. It provides recruitment services for accountancy and finance, banking and financial services, executive search, …
  • Daicel Corporation (4202):企業の財務・戦略的SWOT分析
    Daicel Corporation (4202) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Greencore Group Plc:企業のM&A・事業提携・投資動向
    Greencore Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Greencore Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Pharmascience Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pharmascience Inc (Pharmascience) is a pharmaceutical company which develops, manufactures and markets generic pharmaceutical products. The company offers generic, prescription, over-the-counter and private label OTC products. It offers drugs in therapeutic areas of anti-inflammatory, cancer …
  • Qatar Shipping Co:企業の戦略的SWOT分析
    Qatar Shipping Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Manulife (International) Limited:企業の戦略・SWOT・財務情報
    Manulife (International) Limited - Strategy, SWOT and Corporate Finance Report Summary Manulife (International) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Armetheon Inc-製薬・医療分野:企業M&A・提携分析
    Summary Armetheon Inc (Armetheon) is a drug development company that develops novel small molecule drugs for treatment of cardiovascular diseases with high unmet medical need. The company develops anticoagulants and antibiotics that make use of the antibiotic resistance mechanisms to provide bacteri …
  • Orchid Orthopedic Solutions LLC:医療機器:M&Aディール及び事業提携情報
    Summary Orchid Orthopedic Solutions LLC (Orchid Orthopedic) is a medical device manufacturing company that offers orthopedic and medical device contract design, and manufacturing outsourcing services. The company provides proprietary solutions such as implant bone in-growth coatings, medical device …
  • Aprea AB-製薬・医療分野:企業M&A・提携分析
    Summary Aprea AB (Aprea) discovers and develops novel anticancer compounds targeting the tumor suppressor protein p53. The company’s lead drug candidate includes APR-246, an anti-cancer compound that targets and reactivates the tumor suppressor protein p53, inducing programmed cell death in many hum …
  • Taconic Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Taconic Biosciences Inc (Taconic), formerly Taconic Farms Inc is a research model provider that offers animal health models and laboratory services. The company’s products include taconic transgenic mouse models, emerging models, cryopreserved models, traditional models, diet induced obese, …
  • Ramaco Resources Inc. (METC):企業の財務・戦略的SWOT分析
    Ramaco Resources Inc. (METC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Sunshine Oilsands Ltd (2012):企業の財務・戦略的SWOT分析
    Summary Sunshine Oilsands Ltd (Sunshine Oilsands) is an oil and gas company that develops holdings of oil sands and PN&G leases. The company owns and controls oil sands leases. Its properties include Thickwood, West Ells, Muskwa, Harper, Legend Lake and Portage, among others. Sunshine Oilsands also …
  • Massachusetts Eye and Ear Infirmary-製薬・医療分野:企業M&A・提携分析
    Summary Massachusetts Eye and Ear Infirmary (MEE) is a healthcare service provider that offers primary, medical and surgical care services. The hospital offers services through departments such as ophthalmology, otolaryngology and patient care services. Its patient care services include patient educ …
  • Ignyta Inc (RXDX)-製薬・医療分野:企業M&A・提携分析
    Summary Ignyta Inc (Ignyta), formerly NexDx Inc is a drug manufacturing company that discovers, develops and commercializes new drugs targeting activated genes in cancer cells for the treatment of cancer patients. The company develops products using integrated therapeutic (Rx) and companion diagnost …
  • Redcape Hotel Group:企業の戦略・SWOT・財務情報
    Redcape Hotel Group - Strategy, SWOT and Corporate Finance Report Summary Redcape Hotel Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Bina Puri Holdings Bhd:企業の戦略・SWOT・財務情報
    Bina Puri Holdings Bhd - Strategy, SWOT and Corporate Finance Report Summary Bina Puri Holdings Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Marmon Holdings Inc:企業の戦略・SWOT・財務分析
    Marmon Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Marmon Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • National Aerospace Fasteners Corporation:企業の戦略・SWOT・財務情報
    National Aerospace Fasteners Corporation - Strategy, SWOT and Corporate Finance Report Summary National Aerospace Fasteners Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Shimizu Corporation:企業の戦略・SWOT・財務分析
    Shimizu Corporation - Strategy, SWOT and Corporate Finance Report Summary Shimizu Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆